RAS mutations in human cancers: Roles in precision medicine
- PMID: 31255772
- DOI: 10.1016/j.semcancer.2019.06.007
RAS mutations in human cancers: Roles in precision medicine
Abstract
Ras proteins play a crucial role as a central component of the cellular networks controlling a variety of signaling pathways that regulate growth, proliferation, survival, differentiation, adhesion, cytoskeletal rearrangements and motility of a cell. Almost, 4 decades passed since Ras research was started and ras genes were originally discovered as retroviral oncogenes. Later on, mutations of the human RAS genes were linked to tumorigenesis. Genetic analyses found that RAS is one of the most deregulated oncogenes in human cancers. In this review, we summarize the pioneering works which allowed the discovery of RAS oncogenes, the finding of frequent mutations of RAS in various human cancers, the role of these mutations in tumorigenesis and mutation-activated signaling networks. We further describe the importance of RAS mutations in personalized or precision medicine particularly in molecular targeted therapy, as well as their use as diagnostic and prognostic markers as therapeutic determinants in human cancers.
Keywords: Cancer; HRAS; KRAS; Mutation; NRAS; Oncogene; Personalized medicine; Precision medicine.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Targeting the RAS-dependent chemoresistance: The Warburg connection.Semin Cancer Biol. 2019 Feb;54:80-90. doi: 10.1016/j.semcancer.2018.01.016. Epub 2018 Feb 9. Semin Cancer Biol. 2019. PMID: 29432815 Review.
-
RAS-mediated oncogenic signaling pathways in human malignancies.Semin Cancer Biol. 2019 Feb;54:1-13. doi: 10.1016/j.semcancer.2018.03.001. Epub 2018 Mar 7. Semin Cancer Biol. 2019. PMID: 29524560 Review.
-
Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.Mol Diagn Ther. 2017 Apr;21(2):167-178. doi: 10.1007/s40291-016-0248-6. Mol Diagn Ther. 2017. PMID: 27995550 Review.
-
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):27-38. doi: 10.1093/abbs/gmv090. Epub 2015 Sep 7. Acta Biochim Biophys Sin (Shanghai). 2016. PMID: 26350096 Free PMC article. Review.
-
A model for RAS mutation patterns in cancers: finding the sweet spot.Nat Rev Cancer. 2018 Dec;18(12):767-777. doi: 10.1038/s41568-018-0076-6. Nat Rev Cancer. 2018. PMID: 30420765 Review.
Cited by
-
From targeted therapy to a novel way: Immunogenic cell death in lung cancer.Front Med (Lausanne). 2022 Dec 23;9:1102550. doi: 10.3389/fmed.2022.1102550. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619616 Free PMC article. Review.
-
Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas.Br J Biomed Sci. 2022 Jan 31;79:10208. doi: 10.3389/bjbs.2021.10208. eCollection 2022. Br J Biomed Sci. 2022. PMID: 35996504 Free PMC article.
-
Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma.Front Oncol. 2022 May 18;12:840241. doi: 10.3389/fonc.2022.840241. eCollection 2022. Front Oncol. 2022. PMID: 35664781 Free PMC article.
-
gRASping Depolarization: Contribution of RAS GTPases to Mitotic Polarity Clusters Resolution.Front Cell Dev Biol. 2020 Oct 15;8:589993. doi: 10.3389/fcell.2020.589993. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33178703 Free PMC article. No abstract available.
-
A Novel NRAS Variant Near the Splice Junction in Moroccan Childhood Acute Lymphoblastic Leukemia: A Molecular Dynamics Study.Biochem Genet. 2024 Nov 8. doi: 10.1007/s10528-024-10968-2. Online ahead of print. Biochem Genet. 2024. PMID: 39514082
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous